The director just quit and they have done nothing 8 months. The fact is Gilenya share has gone down in their accounts.
What do they expect when you hire people who are great at schmoozing with the female leaders but do not understand the clinical trials of Gilenya or competition. It was a failure before it started. Are they grasping at straws trying to increase a dismal market share?
